Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines

Advances in Cancer Research

Volumn 128, Issue , 2015, Pages 69-93

  Palena, Claudia ^a   Hamilton, Duane H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brachyury; Cancer vaccines; EMT; Stemness; Therapeutic resistance; Tumor progression

Indexed keywords

BRACHYURY; CANCER VACCINE; POXVIRUS VECTOR; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; 2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; BRACHYURY PROTEIN; BRACHYURY VACCINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; RILIMOGENE GALVACIREPVEC; TAMOXIFEN; TUMOR CELL VACCINE; ANTINEOPLASTIC AGENT; FETOPROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNITY; PRIORITY JOURNAL; TUMOR INVASION; CANCER CELL; CANCER IMMUNIZATION; CANCER PATIENT; CANCER STEM CELL; DRUG MECHANISM; ENZYME SYNTHESIS; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; NONHUMAN; POXVIRIDAE; STEM CELL SELF-RENEWAL; TARGET CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR RECURRENCE; TUMOR RESISTANCE; VIRAL GENE DELIVERY SYSTEM; YEAST; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; EPITHELIAL-MESENCHYMAL TRANSITION; FETAL PROTEINS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-BOX DOMAIN PROTEINS;

EID: 84952714993     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.04.001     Document Type: Chapter

References (112)

1. Akalay I., Janji B., Hasmim M., Noman M.Z., Andre F., De Cremoux P., et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Research 2013, 73:2418-2427.
2. Akalay I., Janji B., Hasmim M., Noman M.Z., Thiery J.P., Mami-Chouaib F., et al. EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy 2013, 9:1104-1106.
3. Barresi V., Vitarelli E., Branca G., Antonelli M., Giangaspero F., Barresi G. Expression of brachyury in hemangioblastoma: Potential use in differential diagnosis. The American Journal of Surgical Pathology 2012, 36:1052-1057.
4. Ben-Hamo R., Gidoni M., Efroni S. PhenoNet: Identification of key networks associated with disease phenotype. Bioinformatics 2014, 30:2399-2405.
5. Bernstein M.B., Chakraborty M., Wansley E.K., Guo Z., Franzusoff A., Mostbock S., et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 2008, 26:509-521.
6. Bilusic M., Heery C.R., Arlen P.M., Rauckhorst M., Apelian D., Tsang K.Y., et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunology, Immunotherapy 2014, 63:225-234.
7. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. The Journal of General Virology 1998, 79(Pt 5):1159-1167.
8. Blanco M.J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J., et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21:3241-3246.
9. Boehm A.L., Higgins J., Franzusoff A., Schlom J., Hodge J.W. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunology, Immunotherapy 2010, 59:397-408.
10. Bolos V., Peinado H., Perez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. Journal of Cell Science 2003, 116:499-511.
11. Braun S., Kentenich C., Janni W., Hepp F., de Waal J., Willgeroth F., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology 2000, 18:80-86.
12. Bukholm I.K., Nesland J.M., Borresen-Dale A.L. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. The Journal of Pathology 2000, 190:15-19.
13. Byers L.A., Diao L., Wang J., Saintigny P., Girard L., Peyton M., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research 2013, 19:279-290.
14. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology 2000, 2:76-83.
15. Cereda V., Vergati M., Huen N.Y., di Bari M.G., Jochems C., Intrivici C., et al. Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine 2011, 29:4992-4999.
16. Chaft J.E., Litvak A., Arcila M.E., Patel P., D'Angelo S.P., Krug L.M., et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clinical Lung Cancer 2014, 15:405-410.
17. Chao M.P., Seita J., Weissman I.L. Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harbor Symposia on Quantitative Biology 2008, 73:439-449.
18. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Research 2009, 69:1302-1313.
19. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003, 22:21-29.
20. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:13820-13825.
21. Cunliffe V., Smith J.C. Ectopic mesoderm formation in Xenopus embryos caused by widespread expression of a Brachyury homologue. Nature 1992, 358:427-430.
22. Disis M.L. Mechanism of action of immunotherapy. Seminars in Oncology 2014, 41(Suppl. 5):S3-S13.
23. Drake C.G., Jaffee E., Pardoll D.M. Mechanisms of immune evasion by tumors. Advances in Immunology 2006, 90:51-81.
24. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
25. Fernando R.I., Castillo M.D., Litzinger M., Hamilton D.H., Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Research 2011, 71:5296-5306.
26. Fernando R.I., Litzinger M., Trono P., Hamilton D.H., Schlom J., Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of Clinical Investigation 2010, 120:533-544.
27. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. The Journal of Clinical Investigation 2010, 120:485-497.
28. Halder S.K., Beauchamp R.D., Datta P.K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005, 7:509-521.
29. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 2013, 369:134-144.
30. Hamilton D.H., Fernando R.I., Schlom J., Palena C. Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. Oncotarget 2014, 6(7):4853-4862. [Epub online], December 26.
31. Hamilton D.H., Huang B., Fernando R.I., Tsang K.Y., Palena C. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Research 2014, 74:2510-2519.
32. Hamilton D.H., Litzinger M.T., Fernando R.I., Huang B., Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: Tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Seminars in Oncology 2012, 39:358-366.
33. Hamilton D.H., Litzinger M.T., Jales A., Huang B., Fernando R.I., Hodge J.W., et al. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013, 4:1777-1790.
34. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
35. Haro A., Yano T., Kohno M., Yoshida T., Koga T., Okamoto T., et al. Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Annals of Surgical Oncology 2013, 20(Suppl. 3):S509-S516.
36. Hartley M.L., Bade N.A., Prins P.A., Ampie L., Marshall J.L. Pancreatic cancer, treatment options, and GI-4000. Human Vaccines & Immunotherapeutics 2014, 10:3347-3353.
37. Heery C.R., Singh H., Marte J.L., Madan R.A., O'Sullivan Coyne G.H., Farsaci B., et al. NCI experience using yeast-brachyury vaccine (GI-6301) in patients with advanced chordoma. Journal of Clinical Oncology 2014, 32:5s. Suppl. abstr 3081.
38. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711-723.
39. Huang B., Cohen J.R., Fernando R.I., Hamilton D.H., Litzinger M.T., Hodge J.W., et al. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death & Disease 2013, 4:e682.
40. Huang R.Y., Wong M.K., Tan T.Z., Kuay K.T., Ng A.H., Chung V.Y., et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death & Disease 2013, 4:e915.
41. Igney F.H., Krammer P.H. Immune escape of tumors: Apoptosis resistance and tumor counterattack. Journal of Leukocyte Biology 2002, 71:907-920.
42. Im E.J., Hanke T. MVA as a vector for vaccines against HIV-1. Expert Review of Vaccines 2004, 3:S89-S97.
43. Iwatsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Science 2010, 101:293-299.
44. Jordan N.V., Johnson G.L., Abell A.N. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 2011, 10:2865-2873.
45. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International Journal of Oncology 2007, 31:277-283.
46. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 2009, 119:1420-1428.
47. Kilic N., Feldhaus S., Kilic E., Tennstedt P., Wicklein D., Wasielewski R., et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. European Journal of Cancer 2011, 47:1080-1085.
48. Kim H.P., Han S.W., Song S.H., Jeong E.G., Lee M.Y., Hwang D., et al. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene 2014, 33:3334-3341.
49. Kispert A., Koschorz B., Herrmann B.G. The T protein encoded by Brachyury is a tissue-specific transcription factor. The EMBO Journal 1995, 14:4763-4772.
50. Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
51. Kwok W.K., Ling M.T., Lee T.W., Lau T.C., Zhou C., Zhang X., et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research 2005, 65:5153-5162.
52. Larocca C., Cohen J.R., Fernando R.I., Huang B., Hamilton D.H., Palena C. An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Molecular Cancer Therapeutics 2013, 12:1805-1815.
53. Larocca C., Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer Journal 2011, 17:359-371.
54. Lee M.Y., Chou C.Y., Tang M.J., Shen M.R. Epithelial-mesenchymal transition in cervical cancer: Correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clinical Cancer Research 2008, 14:4743-4750.
55. Madan R.A., Bilusic M., Heery C., Schlom J., Gulley J.L. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Seminars in Oncology 2012, 39:296-304.
56. Madan R.A., Mohebtash M., Arlen P.M., Vergati M., Rauckhorst M., Steinberg S.M., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. The Lancet Oncology 2012, 13:501-508.
57. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
58. Mayr A., Danner K. Vaccination against pox diseases under immunosuppressive conditions. Developments in Biological Standardization 1978, 41:225-234.
59. McKeon F.D., Kirschner M.W., Caput D. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature 1986, 319:463-468.
60. Mejlvang J., Kriajevska M., Vandewalle C., Chernova T., Sayan A.E., Berx G., et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Molecular Biology of the Cell 2007, 18:4615-4624.
61. Muller C.W., Herrmann B.G. Crystallographic structure of the T domain-DNA complex of the Brachyury transcription factor. Nature 1997, 389:884-888.
62. Nantajit D., Lin D., Li J.J. The network of epithelial-mesenchymal transition: Potential new targets for tumor resistance. Journal of Cancer Research and Clinical Oncology 2014, [Epub ahead of print], October 1. 10.1007/s00432-014-1840y.
63. Nguyen D.X., Bos P.D., Massague J. Metastasis: From dissemination to organ-specific colonization. Nature Reviews. Cancer 2009, 9:274-284.
64. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nature Reviews. Genetics 2007, 8:341-352.
65. Nieto M.A. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013, 342:1234850.
66. Ottaviano Y., Gerace L. Phosphorylation of the nuclear lamins during interphase and mitosis. The Journal of Biological Chemistry 1985, 260:624-632.
67. Palena C., Fernando R.I., Hamilton D.H. An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition. Oncoimmunology 2014, 3:e27220.
68. Palena C., Fernando R.I., Litzinger M.T., Hamilton D.H., Huang B., Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Experimental Biology and Medicine (Maywood, N.J.) 2011, 236:537-545.
69. Palena C., Hamilton D.H., Fernando R.I. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncology 2012, 8:713-722.
70. Palena C., Polev D.E., Tsang K.Y., Fernando R.I., Litzinger M., Krukovskaya L.L., et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clinical Cancer Research 2007, 13:2471-2478.
71. Palena C., Roselli M., Litzinger M.T., Ferroni P., Costarelli L., Spila A., et al. Overexpression of the EMT driver brachyury in breast carcinomas: Association with poor prognosis. Journal of the National Cancer Institute 2014, 106. pii: dju054.
72. Palena C., Schlom J. Vaccines against human carcinomas: Strategies to improve antitumor immune responses. Journal of Biomedicine & Biotechnology 2010, 2010:380697. [Epub 2010] March 16.
73. Peng S.B., Yan L., Xia X., Watkins S.A., Brooks H.B., Beight D., et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 2005, 44:2293-2304.
74. Pinto F., Pertega-Gomes N., Pereira M.S., Vizcaino J.R., Monteiro P., Henrique R.M., et al. T-box transcription factor Brachyury is associated with prostate cancer progression and aggressiveness. Clinical Cancer Research 2014, 20:4949-4961.
75. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews. Cancer 2009, 9:265-273.
76. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 2007, 25:267-296.
77. Rao L., Perez D., White E. Lamin proteolysis facilitates nuclear events during apoptosis. The Journal of Cell Biology 1996, 135:1441-1455.
78. Remondo C., Cereda V., Mostbock S., Sabzevari H., Franzusoff A., Schlom J., et al. Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 2009, 27:987-994.
79. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
80. Roselli M., Fernando R.I., Guadagni F., Spila A., Alessandroni J., Palmirotta R., et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: An opportunity for novel interventions against lung cancer. Clinical Cancer Research 2012, 18:3868-3879.
81. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. International Journal of Cancer 2011, 129:2310-2314.
82. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Seminars in Cancer Biology 2012, 22:396-403.
83. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. Journal of the National Cancer Institute 2012, 104:599-613.
84. Schlom J., Hodge J.W., Palena C., Tsang K.Y., Jochems C., Greiner J.W., et al. Therapeutic cancer vaccines. Advances in Cancer Research 2014, 121:67-124.
85. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of Surgical Oncology 2007, 14:3629-3637.
86. Shanker A., Brooks A.D., Jacobsen K.M., Wine J.W., Wiltrout R.H., Yagita H., et al. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Research 2009, 69:6615-6623.
87. Shibata K., Kajiyama H., Ino K., Terauchi M., Yamamoto E., Nawa A., et al. Twist expression in patients with cervical cancer is associated with poor disease outcome. Annals of Oncology 2008, 19:81-85.
88. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: What's here, what's next?. Current Opinion in Immunology 2015, 33C:23-35.
89. Singh B.H., Gulley J.L. Therapeutic vaccines as a promising treatment modality against prostate cancer: Rationale and recent advances. Therapeutic Advances in Vaccines 2014, 2:137-148.
90. Singh H., Heery C.R., Marte J.L., Farsaci B., Madan R.A., O'Sullivan Coyne G.H., et al. A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. Journal of Clinical Oncology 2014, 32. (Suppl.; abstr e14026).
91. Tan T.Z., Miow Q.H., Miki Y., Noda T., Mori S., Huang R.Y., et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Molecular Medicine 2014, 6:1279-1293.
92. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Reviews. Cancer 2002, 2:442-454.
93. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology 2003, 15:740-746.
94. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
95. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Research 2005, 65:9455-9462.
96. Thomson S., Petti F., Sujka-Kwok I., Epstein D., Haley J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clinical & Experimental Metastasis 2008, 25:843-854.
97. Tirabosco R., Mangham D.C., Rosenberg A.E., Vujovic S., Bousdras K., Pizzolitto S., et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. The American Journal of Surgical Pathology 2008, 32:572-580.
98. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology 2012, 24:207-212.
99. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366:2443-2454.
100. Tucker J.A., Jochems C., Boyerinas B., Fallon J., Greiner J.W., Palena C., et al. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunology, Immunotherapy 2014, 63:1307-1317.
101. Vega S., Morales A.V., Ocana O.H., Valdes F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes & Development 2004, 18:1131-1143.
102. Vujovic S., Henderson S., Presneau N., Odell E., Jacques T.S., Tirabosco R., et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. The Journal of Pathology 2006, 209:157-165.
103. Wansley E.K., Chakraborty M., Hance K.W., Bernstein M.B., Boehm A.L., Guo Z., et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research 2008, 14:4316-4325.
104. Wilson C., Ye X., Pham T., Lin E., Chan S., McNamara E., et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Research 2014, 74:5878-5890.
105. (2013). Open label study to evaluate the safety and tolerability of GI-6301 a vaccine consisting of whole heat-killed recombinant yeast genetically modified to express brachyury protein in adults with solid tumors. Retrieved February 5, 2013. http://www.clinicaltrials.gov.
106. (2014). Safety and tolerability of a modified vaccinia Ankara (MVA)-based vaccine modified to express brachyury and T-cell costimulatory molecules (MVA-Brachyury-TRICOM). Retrieved September 3, 2014. http://www.clinicaltrials.gov.
107. Yang A.D., Fan F., Camp E.R., van Buren G., Liu W., Somcio R., et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clinical Cancer Research 2006, 12:4147-4153.
108. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
109. Yang X.R., Ng D., Alcorta D.A., Liebsch N.J., Sheridan E., Li S., et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nature Genetics 2009, 41:1176-1178.
110. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Developmental Cell 2008, 14:818-829.
111. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
112. Zhang D., LaFortune T.A., Krishnamurthy S., Esteva F.J., Cristofanilli M., Liu P., et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clinical Cancer Research 2009, 15:6639-6648.